We identified a novel mutation of the tumor-associated calcium signal transducer 2 (TACSTD2) gene in a Japanese patient with gelatinous drop-like corneal dystrophy (GDLD). Genetic analysis revealed a novel homozygous mutation (c.798delG, which may result in frameshift mutation p.Lys267SerfsTer4) in the TACSTD2 gene. This mutated gene was devoid of its original function in helping the claudin (CLDN) 1 and 7 proteins transfer from the cytoplasm to the plasma membrane.
Introduction
Gelatinous drop-like corneal dystrophy (GDLD; OMIM:204870) is a rare corneal dystrophy. Most affected patients are Japanese, and the estimated incidence is 1/ 33,000 in Japan 1 . GDLD is an autosomal recessive disease characterized by the deposition of amyloid in the subepithelial region of the bilateral corneas. As amyloid deposition increases and corneal neovascularization covers the corneal surface, visual acuity becomes severely impaired. Repeated lamellar or penetrating keratoplasty is frequently required for most patients. Using positional cloning, we successfully identified the disease-causing gene, tumor-associated calcium signal transducer 2 (TACSTD2;NM_002353), thereby enabling us to investigate the molecular bases of GDLD [2] [3] [4] . To date, 31 different GDLD-causing alterations of the TACSTD2 gene (11 missense, 7 nonsense, and 13 frameshift mutations) have been reported to our knowledge [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] . In this study, we identified a novel homozygous frameshift mutation in the TACSTD2 gene in a Japanese family with GDLD and evaluated the pathogenic effect of the mutation.
Materials and methods
All experimental procedures for the sequencing analysis were approved by the Institutional Review Board for Human Studies at Kyoto Prefectural University of Medicine (approval number RBMR-G-148-1). All experimental procedures for the functional analysis were approved by the Institutional Review Board for gene recombination at Osaka University (approval number 2973). Prior informed consent was obtained from the investigated pedigree member after a detailed explanation of the study protocols, and this study was performed in accordance with the tenets of the Declaration of Helsinki for research involving human subjects.
Genomic DNA was extracted from peripheral blood. Polymerase chain reaction (PCR) was performed with a primer pair against TACSTD2 (M1S1-F-2; 5′-CCT GCA GAC CAT CCC AGA C-3′, M1S1-R-2; 5′-CAG GAA GCG TGA CTC ACT TG-3′), which fully covered the coding region of this gene. The PCR product was purified and bidirectionally sequenced using a Big-Dye Terminator v3.1 cycle sequencing kit (Applied Biosystems, Inc., Foster City, CA) in a 20 μl reaction buffer containing a 2× sequencing mixture and either of the above primers. After ethanol precipitation, the sequence products were electrophoresed on an automated capillary sequencer (Genetic Analyzer; Applied Biosystems). To further confirm the mutation detected by the above sequencing analysis, primer extension analysis was performed using a commercial kit (Applied Biosystems, Inc.) for the 798th nucleotide of the TACSTD2 gene coding region in the normal volunteer and patient with the forward primer.
We constructed lentivirus plasmid vectors that harbor the coding region of the CLDN1 or CLDN7 gene. Then, we coinfected HeLa cells not expressing the CLDN1, CLDN7 and TACSTD2 proteins with those lentivirus vectors and used the Tet-on system to overexpress the wild-type or mutant TACSTD2 gene in an inducible manner. First, HeLa cells were seeded at a density of 2.5 × 10 5 cells per well in a six-well plate and infected with the lentivirus vector expressing the CLDN1 or CLDN7 gene. Four days after the infection, drug selection was performed with 0.5 µg/ml puromycin for 2 weeks. Second, we coinfected those HeLa cells with the lentivirus vector expressing the wild-type or mutated TACSTD2 gene and plenti3.3/TR. Drug selection was performed with 2 µg/ml blasticidin and 500 µg/ml G418 for 2 weeks. The drugselected HeLa cells, which should express the CLDN1 or CLDN7 genes under the control of the CMV promoter as well as the TACSTD2 gene under the control of a tetracycline-inducible promoter, were seeded on a collagen-coated culture slide (Nunc 177402 Lab-Tek Chamber Slide System with Cover Glass Slide Sterile, Thermo Fisher Scientific Inc.) at a density of 1 × 10 4 cells per well. Twenty-four hours after seeding, the cells were induced with 1 μg/ml tetracycline for 24 h. After the induction, the cells were fixed with 4% paraformaldehyde, counterstained with Hoechst 33342 dye and mounted with a commercial mounting medium (ProLong® Gold Antifade Mountant, Thermo Fisher Scientific Inc.). The cells were examined under a fluorescent confocal microscope (ELYRA S.1 / LSM710, Carl Zeiss, Oberkochen, Germany) and photographed under the Tet-on system to overexpress the wild-type or mutant TACSTD2 gene.
The patient was a 44-year-old Japanese male at the time of his first admission to our hospital. His parents were first cousins ( Fig. 1a ). He had already undergone several penetrating keratoplasty (PKP) surgeries prior to admission. Characteristic findings of GDLD, including graft failure, mulberry deposition, and neovascularization, were observed in his left host cornea (Fig. 1b ). In his right eye, neovascularization was marked, and the corneal graft was almost covered by the invading conjunctiva (Fig. 1c) . He underwent six PKP surgeries, two in his right eye at the ages of 24 and 27 and four in his left eye at the ages of 25, 36, 44, and 50. Currently, his left eye has a best-corrected visual acuity of hand motion, and his right eye is blinded by glaucoma.
Results
Sequencing analysis of the TACSTD2 gene revealed that the patient had a novel homozygous deletion of G at the 798th nucleotide position (c.798delG, Fig. 1d ). A singlebase primer extension analysis of the 798th nucleotide of the TACSTD2 gene was performed to confirm the above sequence results (Fig. 1e ). This mutation caused a premature truncation (p.Lys267SerfsTer4, Fig. 1f ) and loss of the transmembrane and PIP2 domains (Fig. 1g ). We confirmed that this mutation was not registered in the public SNP databases (ExAC, 1000Genome, HGVD, ToMmo).
In normal corneas, the TACSTD2 protein binds to the CLDN1 and CLDN7 proteins to prevent the degradation of these two molecules. In the absence of functional TACSTD2, the subcellular localization of the CLDN1 and CLDN7 proteins changes from the cell membrane to the intracellular region 17 . Thus, we examined the subcellular localization of CLDN1 or CLDN7 in the presence of wildtype or p.Lys267SerfsTer4 mutated TACSTD2 using the Tet-on system in HeLa cells that express neither TACSTD2 nor CLDNs. We confirmed the expression of the TACSTD2 protein using the Tet-on system and confirmed cell transfection (data not shown).
Without TACSTD2 expression, we found overexpression of CLDN7 proteins localized at the intracellular region (Fig. 2a, c, e, g) . After wild-type TACSTD2 induction, the distribution of CLDN7 was uniformly spread into the plasma membrane ( Fig. 2b, f, q) . In contrast, p.Lys267SerfsTer4 TACSTD2 induction did not alter the subcellular localization of CLDN7 ( Fig. 2d, h, r) .
The CLDN1 protein exhibited almost the same pattern as the CLDN7 protein. Without TACSTD2 expression, CLDN1 proteins localized in the intracellular region ( Fig.  2i, k, m, o) . After wild-type TACSTD2 induction, CLDN1 spread to the plasma membrane ( Fig. 2j, n, s) . In contrast, the signals were not altered with the mutated TACSTD2 (Fig. 2l, p, t) .
These results strongly indicate that the p.Lys267Serf-sTer4 mutation is deleterious, causing a change in CLDN localization and tight-junction disruption.
Discussion
The patient demonstrated severe amyloid deposition, corneal neovascularization, and decreased epithelial barrier function, which are the characteristic clinical manifestations of GDLD. Remarkable neovascularization and conjunctival invasion in his right eye occurred presumably as a result of cell cycle acceleration in the limbal cornea. He may present with the typical mulberry-type GDLD 18 , which is not specific to this mutation 19 .
The TACSTD2 protein is a type I single transmembrane protein. The mutation examined was a frameshift mutation that led to premature truncation and loss of the transmembrane domain. Therefore, this frameshift mutation was thought to inactivate the TACSTD2 protein. However, the possibility of errors in translation, for In the left eye of the patient (at age 44), we found a typical mulberry-type GDLD cornea with mulberry depositions and neovascularization in the host cornea (white arrowhead) and an ulcer in the graft cornea (white arrow) before our first operation. c In the right eye of the patient (at age 44), remarkable neovascularization was observed and the graft cornea was almost covered by invading conjunctival epithelium with less than 1/4 of the corneal epithelium remaining. Presumably loss of corneal limbal stem cells caused the conjunctival invasion. Without TACSTD2 gene induction, aggregated CLDN7 signals were evident, some of them seems to be in the intracellular organelles (a, c, e, g). After induction of wild-type TACSTD2 gene by tetracyclin, distribution of CLDN7 was spread with more uniformity in cytoplasm and cell membrane (b, f, q). In contrast after induction of p.Lys267SerfsTer4-mutated TACSTD2 gene, aggregated signal is apparent and the change of subcellular localization of CLDN7 was not significant (d, h, r). CLDN1 protein exhibited almost the same subcellular localization as CLDN7. Without TACSTD2 gene induction, CLDN1 signals showed aggregated pattern (i, k, m, o). After induction of wild-type TACSTD2 gene, distribution of CLDN1 showed more uniformity in cytoplasm (j, n, s). CLDN1 signals were not altered by induction of the mutated TACSTD2 gene. The aggregated bodies were apparent (l, p, t) example, due to shifts in the reading frame, shunting of ribosomes, or skipping of stop codons, cannot be denied; therefore, we investigated the subcellular localization of CLDN1 and CLDN7 in HeLa cells. From the functional analysis, we concluded that the mutation in TACSTD2 is indeed pathological.
In conclusion, we report a novel homozygous TACSTD2 gene mutation (c.798delG that can result in a frameshift, p.Lys267SerfsTer4) in a Japanese patient with GDLD who was born to a consanguineous couple. Our functional study revealed that the mutation inactivated the TACSTD2 protein, changing the subcellular localization of the CLDN1 and CLDN7 proteins and thereby presumably disrupting the epithelial barrier function of the corneal epithelium.
